Secondary resistances emerging during treatment are a major problem in oncology. If tumour models can be characterised for their primary resistances to reference therapies, there is a lack of preclinical models for secondary resistances.
Antineo has developed preclinical tumour models resistant to reference immunotherapies from sensitive cells. We have a panel of CDX and syngeneic models which can be used either to assess the efficacy of compounds designed to be used in second line, or to revert the resistances.
